

# Medical marijuana: Do the benefits outweigh the risks?



BRIAN GOODMAN

Limited evidence supports its use for treating some conditions, but risks may be substantial

There is a need for additional treatment options to improve symptoms, enhance the quality of life (QOL), and reduce suffering among patients who have chronic medical illness. Medical marijuana (MM) has the potential to help patients who have certain medical conditions in states where it is legal for prescription by a licensed medical provider.

*Cannabis* has a long history of medicinal use (**Box 1**,<sup>1-12</sup> **page 35**). Two derivatives of the *Cannabis* plant—cannabinoid delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)—are responsible for most of its effects. Some of these effects, including analgesia, decreased muscle spasticity, and reduced eye pressure, have been harnessed for their potential therapeutic effects (**Box 2**,<sup>13-19</sup> **page 36**). As of November 2017, 29 states had legalized *Cannabis* for medical use, and several had legalized its recreational use.<sup>12</sup>

With the increasing availability of MM, psychiatrists are likely to encounter patients who are using it or who will ask them about it. This article reviews evidence related to using MM to treat patients with neuropathic pain; chemotherapy-induced nausea and vomiting (CINV); epilepsy; multiple sclerosis (MS); glaucoma; Crohn's disease; Parkinson's disease; amyotrophic lateral sclerosis; dementia-related behavioral disturbances; posttraumatic stress disorder (PTSD); and anxiety.

## Medical illnesses

**Neuropathic pain.** Chronic neuropathic pain affects an estimated 7% to 8% of adults.<sup>20</sup> Patients with neuropathic pain

### Sheila Gupta

University at Buffalo  
School of Medicine and  
Biomedical Sciences,  
Biochemistry  
Buffalo, New York

### Tiffany Phalen, PA-C

Physician Assistant  
Buffalo Medical Group  
Buffalo, New York

### Sanjay Gupta, MD

Chief Medical Officer  
BryLin Hospital  
Buffalo, New York  
Clinical Professor  
Department of Psychiatry  
School of Medicine and  
Biomedical Sciences  
University at Buffalo  
Buffalo, New York  
Clinical Professor  
SUNY Upstate Medical University  
Syracuse, New York  
Consulting Psychiatrist  
DENT Neurological Institute  
Amherst, New York  
Member, CURRENT PSYCHIATRY  
Editorial Board

#### Disclosures

The authors report no financial relationships with any company whose products are mentioned in this article or with manufacturers of competing products.

## Cannabis: A history of medicinal use

**C**annabis has been cultivated since ancient times, beginning in China and India. The earliest reference of its use for healing purposes may have been in the Chinese Pharmacopeia, circa 1500 BC.<sup>1</sup> In 1839, Dr. William Brooke O'Shaughnessy introduced *Cannabis Indica*, or "Indian hemp," to the western world after a professorship in Calcutta, India.<sup>2</sup> In the early 1840s, an English physician, Dr. John Clendinning, prescribed *Cannabis* for migraine headache.<sup>3</sup> In the 19th and early 20th centuries, several prominent physicians advocated using *Cannabis* for migraines; Sir William Osler did so in his textbook, *The principles and practice of medicine*.<sup>4</sup> It was listed in the U.S. Pharmacopeia in 1850 but removed in 1942.<sup>5,6</sup>

Until 1937, *Cannabis* was used in the United States for medicinal purposes, such as for treating inflamed skin, incontinence, and sexually transmitted diseases.<sup>7</sup> In 1937, the Marihuana Tax Act, which prohibited the production, importation, possession, use, and dispersal of *Cannabis*, was passed.<sup>8</sup>

*Cannabis* became a Schedule I drug under the Controlled Substance Act of 1970.<sup>9</sup>

In 1999, based on available evidence, the Institute of Medicine (IOM) concluded *Cannabis* had less likelihood of dependence than benzodiazepines, opiates, cocaine, or nicotine. The IOM also concluded that the symptoms of withdrawal were mild in comparison with benzodiazepines or opiates. Finally, the IOM stated that *Cannabis* was not a "gateway" drug.<sup>10</sup>

In 1996, California was the first state to reimplement medicinal use of *Cannabis* under the Compassionate Use Act, also known as Proposition 215.<sup>11</sup> This act allowed individuals to retain or produce *Cannabis* for personal consumption with a physician's approval. Many states eventually followed California's lead. As of November 2017, 29 states, the District of Columbia, Guam, and Puerto Rico had regulated *Cannabis* use for medical purposes,<sup>12</sup> and recreational use had been approved in 7 states and the District of Columbia.

are often treated with anticonvulsants, antidepressants, opioids, and local anesthetics<sup>21</sup>; however, these medications may not provide substantial relief. Research has revealed that THC and CBD can improve central and peripheral neuropathic pain, as well as pain associated with rheumatoid arthritis and fibromyalgia.<sup>22</sup>

Wilsey et al<sup>23</sup> evaluated the analgesic effects of smoked MM for neuropathic pain in a small (N = 38) double-blind, randomized controlled trial (RCT). Patients in this study had a preexisting diagnosis of complex regional pain syndrome, spinal cord injury, peripheral neuropathy, or nerve injury. To prevent any unforeseen adverse outcomes related to *Cannabis* use, participants were required to have previous exposure to *Cannabis*. Patients were excluded if they had major mental illness, substance abuse, or other major medical ailments.

Participants smoked high-dose *Cannabis* cigarettes (7% THC), low-dose *Cannabis* cigarettes (3.5% THC), or placebo cigarettes. Pain was measured on a visual analog scale (VAS) that ranged from 0 (no pain) to 100 (worst possible pain). Compared with the placebo group, significant analgesia was achieved in

both *Cannabis* groups ( $P = .016$ ). The high-dose group had greater neurocognitive impairment.

Ware et al<sup>24</sup> conducted a crossover RCT (N = 23) to determine the efficacy of smoked MM for neuropathic pain. Participants had neuropathic pain for at least 3 months that was caused by trauma or surgery, with an average weekly pain intensity score >4 on scale of 0 to 10. Patients with pain due to cancer, nociceptive causes, unstable medical conditions, current substance abuse, history of a psychotic disorder, or suicidal ideation were excluded. Participants were assigned to a 9.4% THC group or a 0% THC group. Pain intensity was evaluated daily via telephone. Participants in the 9.4% THC group had statistically lower pain intensity compared with the 0% THC group ( $P = .023$ ). Common adverse effects reported by those in the 9.4% group included headache, dry eyes, burning sensation, dizziness, numbness, and cough.

In an RCT of vaporized *Cannabis*, 39 patients with a diagnosis of complex regional pain syndrome, thalamic pain, spinal cord injury, peripheral neuropathy, radiculopathy, or nerve injury were assigned

### Clinical Point

THC and CBD can improve central and peripheral neuropathic pain



Discuss this article at  
[www.facebook.com/CurrentPsychiatry](http://www.facebook.com/CurrentPsychiatry)



## Medical marijuana

### Clinical Point

Two synthetic cannabinoids are FDA-approved for treating chemotherapy-induced nausea and vomiting

### Box 2

## The effects of *Cannabis*

**M**arijuana is harvested from the plant *Cannabis sativa* and composed of 400 lipophilic chemical compounds, including phytocannabinoids, terpenoids, and flavonoids.<sup>13</sup> The plant contains compounds termed “cannabinoids.” Two of these derivatives in particular are responsible for most of the effects of marijuana: cannabinoid delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). THC has a comparable structure and binding mechanism to anandamide, a naturally occurring fatty acid neurotransmitter present within the human brain.<sup>14-16</sup> The endogenous endocannabinoid system and its receptors are found throughout the entire body (brain, organs, glands, immune cells, and connective tissues).

THC binds to cannabinoid receptors CB<sub>1</sub> and CB<sub>2</sub>. CB<sub>1</sub> is found predominantly in the CNS. CB<sub>2</sub> is found predominantly outside the CNS and is associated with the immune system.<sup>14-16</sup> The effects of THC include euphoria, relaxation, appetite stimulation, improvement of nausea and vomiting, analgesia, decreased muscle spasticity, and reduced eye pressure.<sup>14,15</sup> CBD may have anxiolytic, antipsychotic, anticonvulsive, and analgesic effects.

The rate of absorption of THC and CBD depends both on the potency of the cannabinoid as well as the mechanism of consumption. *Cannabis* can be administered by multiple routes, including via smoking,

oral ingestion, or IV.<sup>16</sup> When *Cannabis* is smoked (the route for the most rapid delivery), THC is transported from the lungs to the bloodstream and reaches peak concentrations in 3 to 10 minutes. Oral ingestion (capsules, tinctures, sprays, and edibles) has a more flexible onset of action, usually occurring in 30 to 120 minutes, with effects lasting 5 to 6 hours. IV administration has rapid effects; the onset can occur within seconds to minutes, and effects can last 2 to 3 hours. The IV form allows 90% of THC to be distributed in plasma and can rapidly penetrate highly vascularized tissues, such as the liver, heart, fat, lungs, and muscles.

Pharmaceutical manufacturers have used cannabinoid derivatives to produce *Cannabis*-based medications for treating medical conditions. Nabilone, a potent agonist of the CB<sub>1</sub> receptor, became available as a Schedule II medication in 1981 and was approved for patients with chemotherapy-induced nausea and vomiting (CINV).<sup>17</sup> In 1985, dronabinol was introduced as an antiemetic for CINV as well as an appetite stimulant for patients with conditions associated with excessive weight loss.<sup>18</sup> Another option, nabiximols, is an oral mucosal spray that consists of THC and CBD in a 1:1 ratio.<sup>19</sup> Nabiximols is approved in Canada for pain relief in end-stage cancer patients and pain associated with multiple sclerosis.<sup>19</sup>

to a medium-dose (3.53% THC), low-dose (1.29% THC), or placebo group.<sup>25</sup> Serious mental illness, substance abuse, and medical conditions were cause for exclusion. Participants received vaporized marijuana (average 8 to 12 puffs per visit) over 3 sessions. A 30% pain reduction was achieved by 26% of those in the placebo group, 57% of those in the low-dose group, and 61% of individuals in the high-dose group; the difference between placebo and each *Cannabis* group was statistically significant.

**Chemotherapy-induced nausea and vomiting.** Up to 80% of patients who receive chemotherapy experience CINV, which occurs from 24 hours to 7 days after receiving such therapy.<sup>26</sup> CINV negatively influences a patient’s QOL and may impact the decision to continue with chemotherapy. Use of MM can help to diminish vomiting by binding to central CB<sub>1</sub> receptors and averting the pro-emetic effects of dopamine and serotonin.<sup>27</sup>

Two synthetically derived cannabinoids, dronabinol and nabilone, are FDA-approved for treating CINV.

In a small (N = 64) parallel-group RCT, Meiri et al<sup>27</sup> compared dronabinol with the commonly used antiemetic ondansetron and with a combination of dronabinol and ondansetron for treating CINV in adults. The primary outcome was prevention of delayed-onset CINV. Patients were eligible for this study if they had a malignancy that did not involve bone marrow, were receiving treatment with a moderately to highly emetogenic regimen, were not pregnant, and had an estimated life expectancy of at least 6 weeks after chemotherapy. The patients were randomized to 1 of 4 treatment groups: dronabinol alone, ondansetron alone, dronabinol plus ondansetron, or placebo. Overall, 47% to 58% of the active treatment groups improved, compared with 20% of the placebo group. Combination therapy did not provide any benefit beyond any single agent

alone. All active treatments reduced nausea compared with placebo; there was no difference between active treatment groups. This study was limited by low enrollment.

Tramèr et al<sup>28</sup> conducted a systematic review of 30 randomized comparisons of MM with placebo or antiemetics. The reviewed studies were completed between 1975 to 1997 and analyzed a total of 1,366 patients. Nabilone was evaluated in 16 trials; dronabinol was utilized in 13 trials; and IM levonantradol, a synthetic cannabinoid analog of dronabinol, was used in 1 trial. These agents were found to be more effective as an antiemetic compared with prochlorperazine, metoclopramide, chlorpromazine, thiethylperazine, haloperidol, domperidone, or alizapride. In addition, 38% to 90% of patients in these studies preferred MM over the traditional antiemetics.

A Cochrane review<sup>29</sup> suggested that MM may be a viable option for treatment-resistant CINV; however, further studies are needed because current studies have methodological limitations.

**Epilepsy.** Maa and Figi<sup>30</sup> reported a case of a 5-year-old girl who had Dravet syndrome, which resulted in 50 generalized tonic-clonic seizures daily; multiple anticonvulsants did not alleviate these seizures. Because of her recurring seizures, the patient had multiple cognitive and motor delays and needed a feeding tube. In addition to her existing antiepileptic drug regimen, she was started on adjunctive therapy with a sublingual *Cannabis* extract containing a high concentration of CBD. Her seizures decreased from 50 per day to 2 to 3 nocturnal convulsions per month. The treatment enabled her to stop using a feeding tube, resume walking and talking, and sleep soundly.

dos Santos et al<sup>31</sup> reviewed studies of MM for treating epilepsy. One was a double-blind, placebo-controlled trial that included 15 patients ages 14 to 49 who had secondary generalized epilepsy with a temporal lobe focus. Eight patients received 200 to 300 mg/d of oral CBD for 8 to 18 weeks, and 7 received placebo. Seven patients had fewer seizures and 4 had no seizures. Only 1 patient in the placebo group demonstrated any improvement. Another study in this

review included 19 children with treatment-resistant epilepsy: Dravet syndrome (n = 13), Doose syndrome (n = 4), Lennox-Gastaut syndrome (n = 1), or idiopathic epilepsy (n = 1). These patients experienced various types of seizures with a frequency ranging from 2 per week to 250 per day. Overall, 84% of children treated with CBD had fewer seizures: 11% were seizure-free, 42% had a >80% reduction in seizures, and 32% had a 25% to 60% reduction in seizures. Parents also noted additional benefits, including increased attention, improved mood, and improved sleep. CBD was well tolerated in most patients in both studies.

Despite these results, a Cochrane review<sup>32</sup> found that no reliable conclusions can be drawn regarding the efficacy of MM for treating epilepsy.

**Multiple sclerosis.** According to American Academy of Neurology guidelines, physicians may provide MM as an alternative treatment for patients with MS-related spasticity.<sup>33</sup> Multiple studies have tested MM and MM-related extracts for treating spasticity related to MS.<sup>34,35</sup> In a placebo-controlled crossover study, Corey-Bloom et al<sup>34</sup> reported a significant reduction in spasticity, measured using the modified Ashworth scale, in MS patients receiving *Cannabis* cigarettes vs placebo cigarettes ( $P < .0001$ ). However, compared with the placebo group, patients who received MM had significant adverse effects, primarily cognitive impairment ( $P = .003$ ).

In a multicenter RCT (N = 572 patients with refractory MS spasticity), Novotna et al<sup>36</sup> evaluated nabiximols, an oral mucosal spray of a formulated extract of *Cannabis* that contains THC and CBD in a 1:1 ratio. They assessed spasticity using the Numerical Spasticity Rating Scale (NRS). Results were confirmed by measuring the number of daily spasms, self-report of sleep quality, and activities of daily living. After 4 weeks of single-blind treatment, patients who responded to nabiximols ( $\geq 20\%$  improvement in spasticity) were randomized to a placebo group or nabiximols group for 12 additional weeks. After 12 weeks, compared with those who received placebo, those in the nabiximols group experienced a statistically significant

## Clinical Point

According to the American Academy of Neurology, medical marijuana may be considered an alternative treatment for MS-related spasticity



## Medical marijuana

### Clinical Point

Evidence suggests that cannabinoids may facilitate the extinction of aversive memories

### Box 3

## Cannabis for treating glaucoma, Crohn's disease, Parkinson's disease, and amyotrophic lateral sclerosis

**Glaucoma.** In a placebo-controlled study, oromucosal administration of medical marijuana (MM) reduced intraocular pressure from 28 mm Hg to 22 mm Hg, with a duration of action of 3.5 hours.<sup>37</sup> However, the American Academy of Ophthalmologists does not recommend treating glaucoma with MM because the effect is short-lasting, and MM causes significant cognitive impairment compared with other standardized treatments.<sup>38</sup> MM also leads to decreased blood pressure, which lowers blood flow to the optic nerve, thus increasing the risk of blindness.

**Crohn's disease.** A randomized controlled trial (RCT) of MM for Crohn's disease was conducted using the Crohn's Disease Activity Index (CDAI) to assess for remission. In this 8-week study, 21 individuals with Crohn's disease were administered smoked MM (115 mg of delta-9-tetrahydrocannabinol [THC]) or placebo.<sup>39</sup> Eligible patients were at least 20 years old, had active Crohn's disease (CDAI >200), and had not responded to medical treatment for the illness. Compared with those who received placebo, patients who received MM experienced a statistically significant reduction in CDAI scores ( $P < .05$ ). However, at follow-up 2 weeks after the study, when MM was no longer administered, there was no difference in mean CDAI scores between the 2 groups. Five of the 11 patients in the MM group achieved clinical remission, compared with 1 of 10 in the placebo group, but this difference was not statistically significant.

**Parkinson's disease (PD).** According to the American Academy of Neurology, oral *Cannabis* extracts are "probably ineffective" for levodopa-induced dyskinesia in patients with PD.<sup>40</sup> Reported benefits have come mainly from self-report studies. A 2014 survey (22 patients) found a significant reduction in PD symptoms—mainly relief from drug-induced tremor and pain—when measured using the Unified Parkinson's Disease Rating Scale (UPDRS). Patients also reported better sleep and reduced pain (measured with a visual analog scale [VAS]). An exploratory double-blind placebo trial (N = 119) found no difference in mean UPDRS and no difference in any neuroprotective measures.<sup>41</sup> However, the experimental group had a significantly higher quality of life (QOL;  $P = .05$ ). A similar double-blind crossover study that included 19 patients found no significant difference in dyskinesia, as measured with the UPDRS, in the group receiving oral *Cannabis* extract compared with the placebo group.<sup>42</sup>

**Amyotrophic lateral sclerosis (ALS).** A randomized double-blind crossover trial of 27 ALS patients found that an oral THC extract (dronabinol, 5 mg, twice daily) had no significant effects on spasticity, as measured with the VAS.<sup>43</sup> There was also no significant difference between the experimental and placebo groups on number of spasms (also measured with a VAS), quality of sleep (measured with the Sleep Disorders Questionnaire), or QOL (measured with the Amyotrophic Lateral Sclerosis Assessment questionnaire).

reduction in spasticity based on NRS score ( $P = .0002$ ).

For a summary of evidence on MM for treating glaucoma, Crohn's disease, Parkinson's disease, and amyotrophic lateral sclerosis, see *Box 3*<sup>37-43</sup>.

### Psychiatric illnesses

**Dementia-related behavioral disturbances.** A few clinical trials with small sample sizes have found evidence supporting the use of MM compounds for alleviating neuropsychiatric symptoms of patients with dementia. An open-label pilot study of 6 individuals with late-stage dementia who received dronabinol, 2.5 mg/d, for 2 weeks, found a significant reduction (compared

with baseline) in nighttime motor activity as measured with an actometer ( $P < .0028$ ).<sup>44</sup> The secondary Neuropsychiatric Inventory (NPI) assessment found reductions in aberrant motor behavior ( $P = .042$ ), agitation ( $P = .042$ ), and nighttime behaviors ( $P = .42$ ).

A 2014 retrospective analysis of 40 inpatients with dementia-related agitation and appetite loss who were treated with dronabinol (mean dosage: 7.03 mg/d) found reductions in all aspects of agitation, including aberrant vocalization, motor agitation, aggressiveness, and treatment resistance, as measured with the Pittsburgh Agitation Scale ( $P < .0001$ ).<sup>45</sup> The study found no significant improvements in appetite, Global Assessment of Functioning mean score, or number of times patients awoke during the

night. Adverse effects included sedation and delirium.

A RCT of 50 dementia patients with clinically relevant neuropsychiatric symptoms found no significant difference in mean NPI scores between patients given placebo and those who received nabiximols, 1.5 mg, 3 times daily.<sup>46</sup> There were no significant differences found in agitation, QOL, life activities, or caregiver-scored Caregiver Global Impression of Change scale.

In a small RCT, THC was safe and well tolerated in 10 older patients with dementia.<sup>47</sup> A 2009 Cochrane review<sup>48</sup> concluded that there was no evidence for the efficacy of MM in treating the neuropsychiatric symptoms related to dementia.

**PTSD.** There are currently no FDA-approved treatments for PTSD. Preclinical evidence shows that the endocannabinoid system is involved in regulating emotional memory. Evidence also suggests that cannabinoids may facilitate the extinction of aversive memories.<sup>49,50</sup>

In 2009, New Mexico became the first state to authorize the use of MM for patients with PTSD. In a study of patients applying for the New Mexico Medical Cannabis Program, researchers used the Clinician Administered Posttraumatic Scale (CAPS) to assess PTSD symptoms.<sup>51</sup> A retrospective chart review of the first 80 patients evaluated found significant ( $P < .0001$ ) reductions of several PTSD symptoms, including intrusive memories, distressing dreams, flashbacks, numbing and avoidance, and hyperarousal, in the group using MM vs those not using MM. There also was a significant difference in CAPS total score ( $P < .0001$ ). Patients reported a 75% reduction in PTSD symptoms while using MM. This study has several limitations: It was a retrospective review,

## Related Resources

- Nguyen DH, Thant TM. Caring for medical marijuana patients who request controlled prescriptions. *Current Psychiatry*. 2017;16(8):50-51.
- National Institute on Drug Abuse. Marijuana as medicine. <https://www.drugabuse.gov/publications/drugfacts/marijuana-medicine>.

### Drug Brand Names

Alizapride • Litan, Superan	Nabilone • Cesamet
Chlorpromazine • Thorazine	Nabiximols • Sativex
Domperidone • Motilium	Ondansetron • Zofran,
Dronabinol • Marinol,	Zuplenz
Syndros	Prochlorperazine •
Haloperidol • Haldol	Compazine
Metoclopramide • Reglan	Thiethylperazine • Torecan

not an RCT, and patients were prescreened and knew before the study began that MM helped their PTSD symptoms.

In another retrospective study, researchers evaluated treatment with nabilone, 0.5 to 6 mg/d, in 104 incarcerated men with various major mental illnesses; most (91%) met criteria for *Cannabis* dependence.<sup>52</sup> They found significant improvements in sleep and PTSD symptoms.

A double-blind RCT evaluated MM in 10 Canadian male soldiers with PTSD who experienced nightmares despite standard medication treatment. Adjunctive nabilone (maximum dose: 3 mg/d) resulted in a reduction in nightmares as measured by the CAPS recurrent distressing dream of the event item score.<sup>53</sup>

Currently, there are no adequately powered RCTs of MM in a diverse group of PTSD patients. Most studies are open-label, enriched design, and included white male veterans. No well-conducted trials have evaluated patients with noncombat-related PTSD. Most of the relevant literature consists of case reports of *Cannabis* use by patients with PTSD.

continued

## Clinical Point

**Patients indicate that *Cannabis* relieves anxiety, but there is no replicated evidence based on RCTs to support this**

## Bottom Line

Limited evidence suggests medical marijuana (MM) may be beneficial for treating a few medical conditions, including neuropathic pain and chemotherapy-induced nausea and vomiting. There is no clear and convincing evidence MM is beneficial for psychiatric disorders, and *Cannabis* can impair cognition and attention and may precipitate psychosis. The risk of deleterious effects are greater in adolescents.



## Medical marijuana

### Clinical Point

Heavy *Cannabis* use impairs motivation and could precipitate psychosis in vulnerable individuals

**Anxiety disorders.** Patients frequently indicate that smoking *Cannabis* helps relieve their anxiety, although there is no replicated evidence based on double-blind RCTs to support this. However, in rat models CBD has been shown to facilitate extinction of conditioned fear via the endocannabinoid system.<sup>54-56</sup> The mechanism of action is not completely understood. CBD has been shown to have antagonistic action at CB<sub>1</sub> and CB<sub>2</sub> receptors. It may have similar effects on memory extinction and may be an adjunct to exposure therapies for anxiety disorders.

Das et al<sup>57</sup> studied the effects of CBD (32 mg) on extinction and consolidation of memory related to contextual fear in 48 individuals. They found that CBD can enhance extinction learning, and suggested it may have potential as an adjunct to extinction-based therapies for anxiety disorders.

### Caveats: Adverse effects, lack of RCTs

*Cannabis* use causes impairment of learning, memory, attention, and working memory. Adolescents are particularly vulnerable to the effects of *Cannabis* on brain development at a time when synaptic pruning and increased myelination occur. Normal brain development could be disrupted. Some studies have linked *Cannabis* use to abnormalities in the amygdala, hippocampus, frontal lobe, and cerebellum. From 1995 to 2014, the potency of *Cannabis* (THC concentration) increased from 4% to 12%.<sup>58</sup> This has substantial implications for increased abuse among adolescents and the deleterious effects of *Cannabis* on the brain.

Heavy *Cannabis* use impairs motivation and could precipitate psychosis in vulnerable individuals. *Cannabis* use may be linked to the development of schizophrenia.<sup>59</sup>

There are no well-conducted RCTs on the efficacy of MM, and adequate safety data are lacking. There is also lack of consensus among qualified experts. There is soft evidence that MM may be helpful in some medical conditions, including but not limited to CINV, neuropathic pain, epilepsy, and MS-related spasticity. Currently, the benefits of using MM do not appear to outweigh the risks.

### References

1. National Institute on Drug Abuse (NIDA). Marijuana Research Findings 1976. NIDA research monograph 14. <https://archives.drugabuse.gov/sites/default/files/monograph14.pdf>. Published July 1977. Accessed November 15, 2017.
2. O'Shaughnessy WB. On the preparations of the Indian hemp, or gunjah- cannabis indica their effects on the animal system in health, and their utility in the treatment of tetanus and other convulsive diseases. *Prov Med J Retrospect Med Sci*. 1843;5(123):363-369.
3. Clendinning J. Observations on the medical properties of the Cannabis Sativa of India. *Med Chir Trans*. 1843;26:188-210.
4. Osler W, McCrae T. The principles and practice of medicine. 9th ed. New York, NY: D. Appleton and Company; 1921.
5. The pharmacopoeia of the United States of America. 3rd ed. Philadelphia, PA: Lippincott; 1851.
6. The pharmacopoeia of the United States of America. 12th ed. Easton, PA: Mack Printing Company; 1942.
7. Philipson N, Butler RD, Simon C, et al. Medical marijuana: a primer on ethics, evidence, and politics. *Journal Nurse Pract*. 2014;10(9):633-640.
8. Marihuana Tax Act of 1937, Pub L No. 75-238, 75th Cong, 50 Stat 551 (1937).
9. Controlled Substances Act, 21 USC §812.
10. Watson SJ, Benson JA, Joy JE, eds. Marijuana and medicine: assessing the science base. Washington, DC: National Academy Press; 1999.
11. California Proposition 215, the medical marijuana initiative (1996). [https://ballotpedia.org/California\\_Proposition\\_215\\_the\\_Medical\\_Marijuana\\_Initiative\\_\(1996\)](https://ballotpedia.org/California_Proposition_215_the_Medical_Marijuana_Initiative_(1996)). Accessed November 16, 2017.
12. National Conference of State Legislatures. State medical marijuana laws. <http://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx>. Updated September 14, 2017. Accessed November 16, 2017.
13. Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. *Br J Pharmacol*. 2011;163(7):1344-1364.
14. Alger BE. Getting high on the endocannabinoid system. *Cerebrum*. 2013;14. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3997295>. Accessed December 5, 2017.
15. Galal AM, Slade D, Gul W, et al. Naturally occurring and related synthetic cannabinoids and their potential therapeutic applications. *Recent Pat CNS Drug Discov*. 2009;4(2):112-136.
16. Huestis MA. Human cannabinoid pharmacokinetics. *Chem Biodivers*. 2007;4(8):1770-1804.
17. Cesamet [package insert]. Somerset, NJ: Meda Pharmaceuticals; 2013.
18. Marinol [package insert]. Chicago, IL: AbbVie Inc.; 2017.
19. Sativex [package insert]. Mississauga, Ontario: Bayer Inc.; 2015.
20. Torrance N, Ferguson JA, Afolabi E, et al. Neuropathic pain in the community: more under-treated than refractory? *Pain*. 2013;154(5):690-699.
21. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. *Lancet Neurol*. 2015;14(2):162-173.
22. Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: a systematic review and meta-analysis. *JAMA*. 2015;313(24):2456-2473.
23. Wilsey B, Marcotte T, Tsodikov A, et al. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. *J Pain*. 2008;9(6):506-521.
24. Ware MA, Wang T, Shapiro S, et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. *CMAJ*. 2010;182(14):E694-E701.
25. Wilsey B, Marcotte T, Deutsch R, et al. Low-dose vaporized cannabis significantly improves neuropathic pain. *J Pain*. 2013;14(2):136-148.
26. National Cancer Institute. Treatment-related nausea and vomiting (PDQ®)-health professional version. <https://www.cancer.gov/about-cancer/treatment/side-effects/nausea/nausea-hp-pdq>. Updated May 10, 2017. Accessed November 7, 2017.

27. Meiri E, Jhangiani H, Vrendenburgh JJ, et al. Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. *Curr Med Res Opin.* 2007;23(3):533-543.
28. Tramèr MR, Carroll D, Campbell FA, et al. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. *BMJ.* 2001;323(7303):16-21.
29. Smith LA, Azariah F, Lavender VT, et al. Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. *Cochrane Database Syst Rev.* 2015;(11):CD009464.
30. Maa E, Figi P. The case for medical marijuana in epilepsy. *Epilepsia.* 2014;55(6):783-786.
31. dos Santos RG, Hallak JE, Leite JP, et al. Phytocannabinoids and epilepsy. *J Clin Pharm Ther.* 2015;40(2):135-143.
32. Gloss D, Vickrey B. Cannabinoids for epilepsy. *Cochrane Database Syst Rev.* 2014;(3):CD009270.
33. Yadav V, Bever C Jr, Bowen J, et al. Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: report of the guideline development subcommittee of the American Academy of Neurology. *Neurology.* 2014;82(12):1083-1092.
34. Corey-Bloom J, Wolfson T, Gamst A, et al. Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial. *CMAJ.* 2012;184(10):1143-1150.
35. Zajicek J, Ball S, Wright D, et al; CUPID investigator group. Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial. *Lancet Neurol.* 2013;12(9):857-865.
36. Novotna A, Mares J, Ratcliffe S, et al; Sativex Spasticity Study Group. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols\* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. *Eur J Neurol.* 2011;18(9):1122-1131.
37. Merritt JC, Crawford WJ, Alexander PC, et al. Effect of marijuana on intraocular and blood pressure in glaucoma. *Ophthalmology.* 1980;87(3):222-228.
38. American Academy of Ophthalmology. American Academy of Ophthalmology reiterates position that marijuana is not a proven treatment for glaucoma. <https://www.aaof.org/newsroom/news-releases/detail/american-academy-of-ophthalmology-reiterates-posit>. Published June 27, 2014. Accessed May 29, 2017.
39. Naftali T, Bar-Lev Schleider L, Dotan I, et al. Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study. *Clin Gastroenterol Hepatol.* 2013;11(10):1276.e1-1280.e1.
40. Koppel BS, Brust JC, Fife T, et al. Systematic review: efficacy and safety of medical marijuana in certain neurological disorders. Report of the Guideline Development Subcommittee of the American Academy of Neurology. *Neurology.* 2014;82(17):1556-1563.
41. Chagas MH, Zuardi AW, Tumas V, et al. Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial. *J Psychopharmacol.* 2014;28(11):1088-1098.
42. Carroll CB, Bain PG, Teare L, et al. Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. *Neurology.* 2004;63(7):1245-1250.
43. Weber M, Goldman B, Truniger S. Tetrahydrocannabinol (THC) for cramps in amyotrophic lateral sclerosis: a randomised, double-blind crossover trial. *J Neurol Neurosurg Psychiatry.* 2010;81(10):1135-1140.
44. Walther S, Mahlberg R, Eichmann U, et al. Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. *Psychopharmacology (Berl).* 2006;185(4):524-528.
45. Woodward MR, Harper DG, Stolyar A, et al. Dronabinol for the treatment of agitation and aggressive behavior in acutely hospitalized severely demented patients with noncognitive behavioral symptoms. *Am J Geriatr Psychiatry.* 2014;22(4):415-419.
46. van den Elsen GA, Ahmed A, Verkes RJ, et al. Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: a randomized controlled trial. *Neurology.* 2015;84(23):2338-2346.
47. Ahmed AI, van den Elsen GA, Colbers A, et al. Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementia. *Psychopharmacology (Berl).* 2015;232(14):2587-2595.
48. Krishnan S, Cairns R, Howard R. Cannabinoids for the treatment of dementia. *Cochrane Database Syst Rev.* 2009;(2):CD007204.
49. de Bitencourt RM, Pamplona FA, Takahashi RN. A current overview of cannabinoids and glucocorticoids in facilitating extinction of aversive memories: potential extinction enhancers. *Neuropharmacology.* 2013;64:389-395.
50. Fraser GA. The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). *CNS Neurosci Ther.* 2009;15(1):84-88.
51. Greer GR, Grob CS, Halberstadt AL. PTSD symptom reports of patients evaluated for the New Mexico Medical Cannabis Program. *J Psychoactive Drugs.* 2014;46(1):73-77.
52. Cameron C, Watson D, Robinson J. Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder-related insomnia and nightmares, chronic pain, harm reduction, and other indications: a retrospective evaluation. *J Clin Psychopharmacol.* 2014;34(5):559-564.
53. Jetly R, Heber A, Fraser G, et al. The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: a preliminary randomized, double-blind, placebo-controlled cross-over design study. *Psychoneuroendocrinology.* 2015;51:585-588.
54. Bitencourt RM, Pamplona FA, Takahashi RN. Facilitation of contextual fear, memory extinction, and anti-anxiogenic effects of AM404 and cannabidiol in conditioned rats. *Eur Neuropsychopharmacol.* 2008;18(12):849-859.
55. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. *Br J Pharmacol.* 2008;153(2):199-215.
56. Thomas A, Baillie GL, Phillips AM, et al. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. *Br J Pharmacol.* 2007;150(5):613-623.
57. Das RK, Kamboj SK, Ramadas M, et al. Cannabidiol enhances consolidation of explicit fear extinction in humans. *Psychopharmacology (Berl).* 2013;226(4):781-792.
58. ElSohly MA, Mehmedic Z, Foster S, et al. Changes in cannabis potency over the last 2 decades (1995-2014): analysis of current data in the United States. *Biol Psychiatry.* 2016;79(7):613-619.
59. Volkow ND, Swanson JM, Evins AE, et al. Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a review. *JAMA Psychiatry.* 2016;73(3):292-297.